






Specific post-market considerations for AI MDs: Change Management

Melissa Finocchio, Chief Regulatory Officer SOPHIA GENETICS


27 March 2023

What is change?






Lung Cancer is increasingly a collection of rare diseases



Change Management for AI MDs

Multimodality is further increasing the complexity



...and the rate of change





Globally Connected Devices

750+

connected healthcare institutions


countries

±70



Adaptive devices need adaptive change management

- Focus on training & processes
- Continuous growth vs Discrete changes
- Careful monitoring & feedback







THANK YOU / QUESTIONS

Melissa Finocchio

mfinocchio@sophiagenetics.com

Disclaimer

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.





Copy right 2021 by the International Medical Device Regulators Forum.